Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin.

The aim of this study was to evaluate the medium term effects of the selective alpha1-adrenenergic- blocker terazocin on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally for 30 days. The daily dose was 1 mg for the first 7 days, 2 mg for the next 7 days and 5 mg for the remaining period of this clinical trial.

Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.

The aim of this study was to evaluate the medium-term effects of the selective AT1-blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. Plasma ANP levels increased by 15.

Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil.

The aim of this study was to evaluate the long term effects of the selective Ca2+-blocker verapamil on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. At the end of this clinical trial, plasma ANP levels increased by 16.

Effect of the beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide plasma levels in hypertensive patients.

The aim of this study was to evaluate the long-term effects of the selective beta 1-blocker/beta 2-agonist celiprolol on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 200 mg for 30 days. Plasma ANP levels increased by 187% despite the drop in blood pressure, while left atrial and ventricular diameters remained unchanged.

ANP concentrations during interchanging DDD-VVI pacing modes in patients with retrograde ventriculoatrial conduction.

The main reason for the pacemaker syndrome during VVI pacing is the existence of ventriculoatrial conduction (V-AC). Twenty-five patients with a permanent DDD pacemaker and ventriculoatrial conduction were included in the study. IN those patients the hemodynamic changes were evaluated in relation to ANP plasma concentration changes during different modes of pacing.